Strattera

Attention Deficit Hyperactivity Disorder

Treatment

1 FDA approval

20 Active Studies for Strattera

What is Strattera

Atomoxetine

The Generic name of this drug

Treatment Summary

Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD). It is known by the brand name Strattera and works by increasing norepinephrine and dopamine in the brain to reduce symptoms associated with ADHD such as distractibility, hyperactivity, and impulsivity. Atomoxetine has fewer side effects than traditional stimulant medications used to treat ADHD and is considered a safer option for those at risk of substance abuse. It can be used in combination with other treatments such as psychological therapy and cognitive behavior therapy. Atomoxetine is typically used in adults and children who cannot take stimulant medications.

Strattera

is the brand name

image of different drug pills on a surface

Strattera Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Strattera

Atomoxetine

2002

183

Approved as Treatment by the FDA

Atomoxetine, commonly known as Strattera, is approved by the FDA for 1 uses like Attention Deficit Hyperactivity Disorder .

Attention Deficit Hyperactivity Disorder

Helps manage Attention Deficit Hyperactivity Disorder (ADHD)

Effectiveness

How Strattera Affects Patients

Atomoxetine is a drug used to treat Attention Deficit Hyperactivity Disorder (ADHD). It works by increasing the levels of certain chemicals in the brain which can improve symptoms. Taking atomoxetine can increase blood pressure and heart rate, so caution should be taken in patients with conditions like hypertension or cardiovascular disease. It may also cause manic or psychotic symptoms in some cases, or increase the risk of suicidal thoughts. Atomoxetine may also cause severe liver injury, and should not be taken if there are any signs of liver dysfunction.

How Strattera works in the body

Atomoxetine is a medicine used to treat ADHD. It works by blocking the norepinephrine transporter and serotonin transporter, which prevents the reuptake of norepinephrine and serotonin in the brain. This is thought to improve the symptoms of ADHD. Recent studies using positron emission tomography (PET) imaging have also shown that atomoxetine blocks the N-methyl-d-aspartate receptor, which suggests it might also affect the glutamate system within the brain.

When to interrupt dosage

The prescribed dosage of Strattera is dependent upon the determined affliction. The quantity of dosage varies, conforming to the method of administration described in the following table.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

, 10.0 mg, 18.0 mg, 25.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 100.0 mg

Oral, Capsule, Capsule - Oral, , Kit, Kit - Oral

Warnings

Strattera has seven contraindications. Therefore, it should not be administered concurrently with any of the conditions presented in the following table.

Strattera Contraindications

Condition

Risk Level

Notes

Cardiovascular Diseases

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

Pheochromocytoma

Do Not Combine

Hyperthyroidism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Atomoxetine may interact with Pulse Frequency

There are 20 known major drug interactions with Strattera.

Common Strattera Drug Interactions

Drug Name

Risk Level

Description

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Atomoxetine.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Atomoxetine.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Atomoxetine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Atomoxetine.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Hydroxyzine.

Strattera Toxicity & Overdose Risk

There have been fatalities reported from mixing atomoxetine with other drugs, but no deaths from taking too much atomoxetine alone. If an overdose is suspected, people may experience seizures, stomach issues, sleepiness, dizziness, shaking, or abnormal behavior. They may also have an increased heart rate, widened pupils, dry mouth, hyperactivity, or agitation. Rarely, people have experienced a prolonged heartbeat, confusion, or hallucinations. If an overdose is suspected, contact a poison control center for advice. Dialysis is not likely to help with an atomoxetine overdose.

image of a doctor in a lab doing drug, clinical research

Strattera Novel Uses: Which Conditions Have a Clinical Trial Featuring Strattera?

77 active clinical trials are currently examining the potential of Strattera to alleviate Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Strattera Reviews: What are patients saying about Strattera?

5

Patient Review

3/21/2022

Strattera for Attention Deficit Disorder with Hyperactivity

This medication was exactly what I needed to finally address my Obsessive Compulsive Disorder and ADHD symptoms. It's really improved my quality of life, would highly recommend it to others in a similar situation.

4

Patient Review

5/8/2022

Strattera for Attention Deficit Disorder with Hyperactivity

I've only been on this medication for two weeks, but it has already done wonders for my organization and focus. Before, I was a total mess with ADHD, but now I can actually get things done!

3.7

Patient Review

4/12/2022

Strattera for Attention Deficit Disorder with Hyperactivity

I've only been on this medication for a week, and the side effects are really bad. I constantly feel like I need to urinate but can't, and I'm bloated, constipated, and nauseous. My doctor said things will even out in time, but the pain when I try to urinate is unbearable. Has anyone else had this problem?

3.3

Patient Review

5/4/2022

Strattera for Attention Deficit Disorder with Hyperactivity

Though this drug is effective, the side effects are really tough to deal with. I have to be very careful about when I take it and how much I eat beforehand. If I wait too long between doses, or if I don't eat enough, I get incredibly disoriented and dizzy. The pills are also quite large and hard to swallow.

3

Patient Review

7/12/2022

Strattera for Attention Deficit Disorder with Hyperactivity

I'm still having some issues with forgetfulness and fatigue, which is really frustrating. I was hoping this medication would help me more.

2.3

Patient Review

2/27/2022

Strattera for Attention Deficit Disorder with Hyperactivity

I experienced a lot of the side effects. My feet were numb and sometimes I couldn't feel them when driving, which was really scary. Also, the left side of my face felt numb and droopy. My head and right side of my body would shake, and my heart rate would skyrocket. I thought I was having mini strokes or seizures. Strattera is not for me, and I would advise others to do their research before taking it.

2.3

Patient Review

12/22/2021

Strattera for Attention Deficit Disorder with Hyperactivity

I found that this medication made me more tired and anxious than usual, which was the opposite of what I needed. Additionally, it did nothing to help my ADHD symptoms. However, when I stopped taking it I noticed an immediate change for the better in my mood.

2.3

Patient Review

7/6/2022

Strattera for Attention Deficit Disorder with Hyperactivity

I saw no benefits from this medication. In fact, it regularly gave me headaches. The worst part was the erectile dysfunction; I could get hard, but then it would fade away almost immediately regardless of stimulation. As you can imagine, my wife wasn't thrilled either.

2

Patient Review

10/2/2022

Strattera for Attention Deficit Disorder with Hyperactivity

I didn't have great results with this medication. I started at 20mg and then was raised to 30mg, but I only experienced severe headaches and constipation.

1

Patient Review

6/12/2022

Strattera for Attention Deficit Disorder with Hyperactivity

This medication was really tough for me to deal with. The side effects were really bad in the third month, to the point where I couldn't sleep and when I did, I would wake up sweating or feeling frozen. I was tired all the time and my depression got worse. I also felt paranoid all the time and had mood swings. Some days I felt like I was drunk because lights would bother my eyes. And on top of all that, I didn't have an appetite most of the time.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about strattera

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Strattera make you feel like?

"The most commonly reported side effects of Strattera are nausea, vomiting, abdominal pain, decreased appetite, constipation, headache, dry mouth, tiredness, and sleepiness. Strattera has been associated with an increased risk of suicidal thoughts or behavior in children and adolescents with ADHD."

Answered by AI

Is Strattera a stimulant or depressant?

"Strattera is a medication used to treat symptoms of attention deficit hyperactivity disorder (ADHD or ADD), including distractibility, impulsivity, and hyperactivity, in children, teens, and adults."

Answered by AI

What does Strattera do to you?

"Strattera works by increasing the amount of norepinephrine, an important chemical in the brain, which appears to help ADHD by increasing attention span and reducing impulsive behavior and hyperactivity."

Answered by AI

Is Strattera and Adderall the same thing?

"Both Strattera and Adderall are effective for treating ADHD; however, Strattera does not contain amphetamine, which means it is less likely to be abused or cause dependence, tolerance, or withdrawal symptoms on discontinuation."

Answered by AI

Clinical Trials for Strattera

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Strattera clinical trials?

We made a collection of clinical trials featuring Strattera, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Strattera clinical trials?

We made a collection of clinical trials featuring Strattera, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Strattera clinical trials?

We made a collection of clinical trials featuring Strattera, we think they might fit your search criteria.
Go to Trials